Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3632 in Advanced Haematologic Malignancies with HOX Overexpression
2025-521299-76-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of AZD3632 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and 1 more (3 arms), sponsored by AstraZeneca. Planned start Dec 2025; status: authorised.
02
Drugs
AZD3632
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2025-521299-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521299-76-00.